Magic Mushrooms for Parkinson’s? What to Know About Psilocybin Therapy

Psilocybin, the active compound in “magic mushrooms,” is being researched for its potential to help treat depression in people with Parkinson’s disease. Dr. Ellen Bradley, a psychiatrist at the University of California, San Francisco, is leading a clinical trial to explore its effects. The Michael J. Fox Foundation is funding this trial, which has expanded to a second site at Yale University. How Psilocybin Works Psilocybin is a psychedelic that alters consciousness by interacting with serotonin receptors, potentially leading to mood improvements and lasting effects. It has been shown in pre-clinical studies to reduce inflammation and promote brain cell health. Researchers believe that psilocybin might help reduce brain inflammation and improve neuroplasticity in Parkinson's patients, possibly addressing both depression and neurodegeneration associated with the disease. The Ongoing Clinical Trial While clinical trials have shown promise for treating depression in general, no studies have yet focused on Parkinson’s patients. The current trial will assess psilocybin’s safety and effectiveness, as well as its potential to impact other Parkinson’s symptoms. Participants receive psilocybin alongside psychotherapy in a controlled environment. Microdosing: What You Should Know While there’s growing interest in microdosing psilocybin, its effects are not well understood, especially for Parkinson’s patients. Dr. Bradley cautions that the safety and dosage for microdosing are still unclear and encourages people to consult their doctors before trying any new treatments. Other Psychedelic Research The Michael J. Fox Foundation is also funding research on other psychedelics like ketamine for Parkinson’s-related depression.